For IHC-P: Use at an assay dependent dilution. Perform heat mediated antigen retrieval before commencing with IHC staining protocol (0.1 M citrate buffer at 95C in water bath for 20 min). Avoid nonspecific binding by incubating in normal rabbit anti-mouse serum. Incubate primary antibody overnight and use a biotin-streptavidin amplification kit. Block endogenous peroxidase with 0.3% H2O2 for 30 minutes. For IP: Use at an assay dependent dilution. For WB: 1:500-1:3000. This antibody recognizes full-length BRCA1, a 220-kDa nuclear phosphoprotein. Optimal dilutions/concentrations should be determined by the researcher.
This antibody recognizes full-length BRCA1, a 220-kDa nuclear phosphoprotein. Mutations in this tumor suppressor gene greatly increase the risk of breast cancer.
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1 mg/ml (Please refer to the vial label for the specific concentration.)
Protein fragment expressed in E. coli corresponding to amino acids 341-748.
Protein G purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
BRCA1 DNA repair associated , BRCAI , BRCC1 , BROVCA1 , FANCS , IRIS , PNCA4 , PPP1R53 , PSCP , RNF53
Nucleus , Cytoplasm
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2009]